Literature DB >> 34383902

Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Chloé Dimeglio1,2, Fabrice Herin3, Isabelle Da-Silva1, Isabelle Jougla3, Claire Pradere3, Marion Porcheron1, Guillaume Martin-Blondel2,4, Sabine Chapuy-Regaud1, Jacques Izopet1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34383902      PMCID： PMC8385956          DOI： 10.1093/cid/ciab705

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.

Authors:  Niklas Worm Andersson; Emilia Myrup Thiesson; Mona Vestergaard Laursen; Stine Hasling Mogensen; Jesper Kjær; Anders Hviid
Journal:  BMJ       Date:  2022-07-13

2.  Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.

Authors:  Sabine Chapuy-Regaud; Marcel Miédougé; Florence Abravanel; Isabelle Da Silva; Marion Porcheron; Judith Fillaux; Chloé Diméglio; Jacques Izopet
Journal:  Microbiol Spectr       Date:  2021-12-22

3.  Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.

Authors:  Nasamon Wanlapakorn; Nungruthai Suntronwong; Harit Phowatthanasathian; Ritthideach Yorsaeng; Preeyaporn Vichaiwattana; Thanunrat Thongmee; Chompoonut Auphimai; Donchida Srimuan; Thaksaporn Thatsanatorn; Suvichada Assawakosri; Sitthichai Kanokudom; Yong Poovorawan
Journal:  Hum Vaccin Immunother       Date:  2022-02-24       Impact factor: 3.452

4.  Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant.

Authors:  Nassim Kamar; Florence Abravanel; Olivier Marion; Raphaelle Romieu-Mourez; Chloé Couat; Arnaud Del Bello; Jacques Izopet
Journal:  JAMA Netw Open       Date:  2021-11-01

Review 5.  'Mix and Match' vaccination: Is dengue next?

Authors:  Camila D Odio; Leah C Katzelnick
Journal:  Vaccine       Date:  2022-10-01       Impact factor: 4.169

Review 6.  Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Authors:  Thuy Trang Nguyen; Trang Ho Thu Quach; Thanh Mai Tran; Huynh Ngoc Phuoc; Ha Thi Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Biomed Pharmacother       Date:  2022-01-19       Impact factor: 6.529

7.  Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.

Authors:  Ulrika Marking; Sebastian Havervall; Nina Greilert-Norin; Henry Ng; Kim Blom; Peter Nilsson; Mia Phillipson; Sophia Hober; Charlotta Nilsson; Sara Mangsbo; Wanda Christ; Jonas Klingström; Max Gordon; Mikael Åberg; Charlotte Thålin
Journal:  Vaccines (Basel)       Date:  2022-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.